Relief Therapeutics and NeuroX Merge to Create AI-Driven Neurotherapeutics Powerhouse

The merger between Relief Therapeutics and NeuroX (successor to MindMaze) creates a new entity with a highly asymmetric ownership structure, where NeuroX shareholders will hold 91% and Relief shareholders 9%, valuing NeuroX at CHF 1 billion and Relief at CHF 100 million, for a total transaction value of CHF 1.1 billion according to the press release. This 91% control provides decisive authority to drive execution of strategic objectives, including deploying solutions to 250+ hospitals and securing U.S. reimbursement code CAT-3. However, the dominance of NeuroX shareholders introduces critical integration risks and creates dependency on securing CHF 250 million in new equity funding, with the merger expected to close in December 2025 according to financial reports. Failure to meet these thresholds-such as delays in closing, integration challenges, or funding shortfalls-could derail the entire scalability engine and impact the long-term growth trajectory of the combined company.

The neurotherapeutics landscape is undergoing a pivotal shift as Relief Therapeutics and NeuroX, the successor to pioneering brain tech firm MindMaze, merge to form a uniquely positioned AI-driven platform. This strategic combination, valued at a total enterprise CHF 1.1 billion (NeuroX at CHF 1 billion, Relief at CHF 100 million), creates a publicly traded leader aiming to revolutionize neurological disease treatment by fusing digital therapeutics with traditional biopharma. The new entity, MindMaze Therapeutics, leverages NeuroX's established technology with 250+ hospital deployments and a newly secured U.S. reimbursement code (CAT-3), integrating it with Relief's pharmaceutical development expertise to accelerate precision medicine solutions. Crucially, the merger taps into MindMaze's substantial USD 350 million-plus research and development pipeline, providing a deep well of clinical validation to de-risk innovation and scale impact. While the combined platform targets a significant market opportunity, its success hinges on overcoming adoption barriers; current penetration rates for digital neurotherapeutics remain below the critical 15% threshold needed for widespread clinical integration and reimbursement viability. This merger represents not just a business combination, but a calculated move to dominate a nascent field where technological integration and proven clinical outcomes will define the winners.

The convergence of AI-driven neuroscience and established biopharma marks a pivotal shift in neurotherapeutics, now crystallized by Relief Therapeutics and NeuroX's (formerly MindMaze) landmark business combination. This strategic merger, valued at CHF 1.1 billion with NeuroX contributing approximately CHF 1 billion and Relief valued at CHF 100 million, aims to create a dominant digital neurotherapeutics platform with 250+ hospital deployments globally and the critical U.S. CAT-3 reimbursement code positioning. Shareholder approval has paved the way for the December 2025 closing, initiating an aggressive operational roadmap. Central to this plan is securing CHF 250 million in new equity funding from Global Emerging Markets and Relief itself. Leadership is firmly established with Alexandre Capet appointed as CEO and Frédéric Condolo as Chief Technology Officer, guiding the newly named MindMaze Therapeutics forward. A joint press conference on November 25, 2025 serves as the primary communication event to unveil the strategic vision and catalyze momentum ahead of the December closing. This sequence of approvals, funding, leadership activation, and public unveiling defines the immediate regulatory and operational execution pathway for the combined entity.